Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
2026
Month
1
2
3
4
5
6
7
8
9
10
11
12
2026.06.04
Boan Biotech Out-licenses Its Dulaglutide Injection in the U.S.
2026.06.01
Boan Biotech Presents Updated Phase I Clinical Data for BA1301 (Anti-CLDN18.2 ADC) at the 2026 ASCO Annual Meeting
2026.05.29
Boan Biotech Submits a Biologics License Application for Two Denosumab Biosimilars in the U.S.
26
2026-05
Boan Biotech’s Boluojia® Newly Approved in China for Treating Bone Metastases from Solid Tumors and Multiple Myeloma
27
2026-04
Boan Biotech Announces CDE Acceptance of Phase Ⅱ Clinical Trial Application for BA1106 in Combination with BA1104 for NSCLC
31
2026-03
Boan Biotech Announces 2025 Financial Results
09
2026-01
Boan's Denosumab (60mg) Approved for Market Launch in Bolivia
10
2025-12
Boan Biotech Grants NKF Exclusive Rights to Commercialize Two Denosumab Drugs in the US
26
2025-11
Boan Biotech’s Boyoujing
®
Approved for Marketing in China for the Treatment of nAMD and DME
07
2025-11
Marketing Authorization Applications for Boan Biotech’s Two Denosumab Injections Accepted in the UK
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
